Intelligent Bio Solutions (INBS) Stock Price, News & Analysis

Company Overview

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Key Stats

• Today's Range: $1.38 to $1.47
• 50-Day Range: $1.27 to $1.70
• 52-Week Range: $1.00 to $11.70
• Volume: 85,759 shs
• Average Volume: 62,304 shs
• Market Capitalization: $6.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Intelligent Bio Solutions Stock Analysis - MarketRank™

Intelligent Bio Solutions scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Intelligent Bio Solutions.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intelligent Bio Solutions are expected to grow in the coming year, from ($1.25) to $0.35 per share.

Price to Book Value per Share Ratio

Intelligent Bio Solutions has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.09% of the float of Intelligent Bio Solutions has been sold short.

Short Interest Ratio / Days to Cover

Intelligent Bio Solutions has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intelligent Bio Solutions has recently decreased by 5.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intelligent Bio Solutions does not currently pay a dividend.

Dividend Growth

Intelligent Bio Solutions does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.09% of the float of Intelligent Bio Solutions has been sold short.

Short Interest Ratio / Days to Cover

Intelligent Bio Solutions has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intelligent Bio Solutions has recently decreased by 5.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.05

News Sentiment

Intelligent Bio Solutions has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Intelligent Bio Solutions this week, compared to 1 article on an average week.

Search Interest

1 people have searched for INBS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intelligent Bio Solutions insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.28% of the stock of Intelligent Bio Solutions is held by insiders.

Percentage Held by Institutions

Only 32.97% of the stock of Intelligent Bio Solutions is held by institutions.

INBS Stock Analysis - Frequently Asked Questions

How have INBS shares performed this year?

Intelligent Bio Solutions' stock was trading at $1.40 at the beginning of 2025. Since then, INBS stock has increased by 4.3% and is now trading at $1.46.
View the best growth stocks for 2025 here.

How were Intelligent Bio Solutions' earnings last quarter?

Intelligent Bio Solutions Inc. (NASDAQ:INBS) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.17. The firm earned $872.29 million during the quarter. Intelligent Bio Solutions had a negative net margin of 288.35% and a negative trailing twelve-month return on equity of 147.50%.

When did Intelligent Bio Solutions' stock split?

Shares of Intelligent Bio Solutions reverse split on Monday, January 29th 2024. The 1-12 reverse split was announced on Monday, January 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Intelligent Bio Solutions?

Shares of INBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Intelligent Bio Solutions own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intelligent Bio Solutions investors own include SoFi Technologies (SOFI), Plug Power (PLUG), Allarity Therapeutics (ALLR), Adial Pharmaceuticals (ADIL), AMC Entertainment (AMC), ARMOUR Residential REIT (ARR) and BIOLASE (BIOL).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 2/14/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:INBS
• CUSIP: N/A
• CIK: 1725430
• Web: gbs.inc
• Phone: 646-828-8258
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,160,000.00
• Net Margins: -288.35%
• Pretax Margin: -289.34%
• Return on Equity: -147.50%
• Return on Assets: -81.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: $3.11 million
• Price / Sales: 2.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.37 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 4,390,000
• Free Float: 4,375,000
• Market Cap: $6.39 million
• Optionable: Not Optionable
• Beta: 4.69